Blueprint Medicines Corp

NASDAQ:BPMC   10:07:31 AM EDT
93.13
-1.12 (-1.19%)
Products, Strategic Combinations

Zai Lab And Blueprint Medicines Announce Agreement For BLU-945 And BLU-701 In Greater China

Published: 11/09/2021 13:51 GMT
Blueprint Medicines Corp (BPMC) - Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for Blu-945 and Blu-701 in Greater China.
Zai Lab - Blueprint Medicines to Receive $25 Million Upfront Payment, Up to $590 Million in Potential Future Milestone Payments, and Royalties.
Zai Lab - Obtains Exclusive Rights to Develop and Commercialize Blu-945 and Blu-701 in Greater China.
Zai Lab - Will Be Responsible for All Development Costs for Blu-945 and Blu-701 Occurring in Greater China.